Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

linrodostat (BMS-986205)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

BMS, Ono Pharma

Drug class:

IDO1 inhibitor

Related drugs:

‹

›

IFNG gene signature overexpression	Lymphoma	IFNG gene signature overexpression	Lymphoma	nivolumab + BMS-986205 Sensitive: C3 – Early Trials nivolumab + BMS-986205 Sensitive : C3	nivolumab + BMS-986205 Sensitive: C3 – Early Trials nivolumab + BMS-986205 Sensitive : C3
IFNG gene signature overexpression	Head and Neck Cancer	IFNG gene signature overexpression	Head and Neck Cancer	nivolumab + BMS-986205 Sensitive: C3 – Early Trials nivolumab + BMS-986205 Sensitive : C3	nivolumab + BMS-986205 Sensitive: C3 – Early Trials nivolumab + BMS-986205 Sensitive : C3
IFNG gene signature overexpression	Cervical Cancer	IFNG gene signature overexpression	Cervical Cancer	nivolumab + BMS-986205 Sensitive: C3 – Early Trials nivolumab + BMS-986205 Sensitive : C3	nivolumab + BMS-986205 Sensitive: C3 – Early Trials nivolumab + BMS-986205 Sensitive : C3
IFNG gene signature overexpression	Urothelial Cancer	IFNG gene signature overexpression	Urothelial Cancer	nivolumab + BMS-986205 Sensitive: C3 – Early Trials nivolumab + BMS-986205 Sensitive : C3	nivolumab + BMS-986205 Sensitive: C3 – Early Trials nivolumab + BMS-986205 Sensitive : C3
IFNG gene signature overexpression	Melanoma	IFNG gene signature overexpression	Melanoma	nivolumab + BMS-986205 Sensitive: C3 – Early Trials nivolumab + BMS-986205 Sensitive : C3	nivolumab + BMS-986205 Sensitive: C3 – Early Trials nivolumab + BMS-986205 Sensitive : C3
IFNG gene signature overexpression	Pancreatic Cancer	IFNG gene signature overexpression	Pancreatic Cancer	nivolumab + BMS-986205 Sensitive: C3 – Early Trials nivolumab + BMS-986205 Sensitive : C3	nivolumab + BMS-986205 Sensitive: C3 – Early Trials nivolumab + BMS-986205 Sensitive : C3
IFNG gene signature overexpression	Renal Cell Carcinoma	IFNG gene signature overexpression	Renal Cell Carcinoma	nivolumab + BMS-986205 Sensitive: C3 – Early Trials nivolumab + BMS-986205 Sensitive : C3	nivolumab + BMS-986205 Sensitive: C3 – Early Trials nivolumab + BMS-986205 Sensitive : C3
PD-L1 expression	Bladder Cancer	PD-L1 expression	Bladder Cancer	nivolumab + BMS-986205 Sensitive: C3 – Early Trials nivolumab + BMS-986205 Sensitive : C3	nivolumab + BMS-986205 Sensitive: C3 – Early Trials nivolumab + BMS-986205 Sensitive : C3